603233.SH
大参林
SSE · Healthcare · Biotechnology · CN
CNY 17.36
−1.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.5B | 27.5B | 26.5B | 24.5B | 21.2B |
| Cost of Revenue | 18.0B | 18.1B | 17.4B | 15.7B | 13.2B |
| Gross Profit | 9.5B | 9.4B | 9.1B | 8.8B | 8.0B |
| Operating Expenses | |||||
| R&D Expense | 42.1M | 41.3M | 51.7M | 80.9M | 74.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.2B | 1.2B | 1.2B | 1.2B | 1.1B |
| Selling & Marketing Expense | 6.0B | 6.0B | 6.2B | 5.6B | 5.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 7.6B | 7.5B | 7.8B | 7.2B | 6.6B |
| Cost and Expenses | 25.6B | 25.6B | 25.2B | 22.9B | 19.8B |
| Operating Income (EBIT) | 1.9B | 1.9B | 1.4B | 1.6B | 1.4B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.9B | 1.8B | 1.3B | 1.6B | 1.4B |
| Income Tax Expense | 502.2M | 490.5M | 359.7M | 397.1M | 335.6M |
| Bottom Line | |||||
| Net Income | 1.3B | 1.2B | 914.8M | 1.2B | 1.0B |
| Earnings from Cont. Ops | 1.4B | 1.4B | 979.9M | 1.2B | 1.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.3B | 1.2B | 914.8M | 1.2B | 1.0B |
| Per Share | |||||
| Basic EPS | CN¥1.13 | CN¥1.08 | CN¥0.81 | CN¥1.03 | CN¥0.91 |
| Diluted EPS | CN¥1.13 | CN¥1.08 | CN¥0.81 | CN¥1.03 | CN¥0.91 |
| Revenue Per Share | CN¥24.23 | CN¥24.05 | CN¥23.46 | CN¥21.66 | CN¥18.67 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | 2.4B | 1.9B | 3.3B | 1.9B |
| D&A | — | 536.8M | 569.1M | 1.7B | 461.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026